Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?
Publication date: November 2026 Source: Value in Health, Volume 29, Issue 11 Author(s): Isa Maria Steiner, Benjamin Birkner, Mateo Wittig Martinez, Tom Stargardt
Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?. // Value in Health. – URL: https://www.sciencedirect.com/science/article/pii/S1098301526025246?dgcid=rss_sd_all
Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?. Value in Health. https://www.sciencedirect.com/science/article/pii/S1098301526025246?dgcid=rss_sd_all
“Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?.” Value in Health.
@article{article70974,
title = {Physician-Led Switching From Reference Biologics to Biosimilars: What Is the Effect on Selected Health-Related Outcomes and Costs for Patients With Inflammatory Bowel Disease in Germany?},
journal = {Value in Health},
url = {https://www.sciencedirect.com/science/article/pii/S1098301526025246?dgcid=rss_sd_all}
}
Abstract Aim Discretionary foods and beverages contribute to poor diet quality and chronic disease. In Australia, intake exceeds dietary guideline recommendations and is unlikely to improve without substantial intervention. We examined...
ABSTRACT Background Ultra‐processed foods (UPFs) are a leading contributor to diet‐related chronic disease and socio‐ecological harm. Despite increasing recognition of these impacts, regulatory responses remain fragmented, focused on...